Evidence map›Paper›PMID 38948778›Full record

ArticlebioRxiv : the preprint server for biology2024

TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.

Maria Gonzalez-Orozco, Hsiang-Chi Tseng, Adam Hage, Hongjie Xia, Padmanava Behera, Kazi Afreen, Yoatzin Peñaflor-Tellez, Maria I Giraldo, Matthew Huante, Lucinda Puebla-Clark and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Maria Gonzalez-OrozcoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0001-7299-3361
Hsiang-Chi TsengCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ.ORCID 0000-0001-7745-413X
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0001-7668-892X
Hongjie XiaDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-2520-7038
Padmanava BeheraCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ.
Kazi AfreenCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ.
Yoatzin Peñaflor-TellezCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ.ORCID 0009-0006-9494-3748
Maria I GiraldoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-9736-3160
Matthew HuanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-6604-9603
Lucinda Puebla-ClarkDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-5363-3026
Sarah van TolDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-9905-920X
Abby OdleCenter for Virus-Host-Innate-Immunity, RBHS Institute for Infectious and Inflammatory Diseases, and Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ.ORCID 0000-0003-0526-9503
Matthew CrownHub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK.ORCID 0000-0002-5091-6282
Natalia TeruelDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.ORCID 0000-0003-3485-973X
Thomas R SheliteDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX.
Vineet MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0001-8803-7606
Mark EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-5338-1332
Janice J EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.
Rafael J NajmanovichDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Canada.ORCID 0000-0002-6971-7224
Matthew BashtonHub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK.ORCID 0000-0002-6847-1525
Robin StephensDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0001-8036-600X
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX.
Alexander N FreibergDepartment of Pathology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0001-8413-8960
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX.ORCID 0000-0002-5058-5444

Funding

Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus DiseaseP01AI150585 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2021 to 2025
$11.3M
UTMB WOMEN'S HEALTH RESEARCH SCHOLARS PROGRAMK12HD052023 · NICHD · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BERENSON, ABBEY B · 2005 to 2023
$8.1M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
The Role of the Host Ubiquitin System in Promoting SARS-CoV-2 Replication and PathogenesisR01AI166668 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2021 to 2025
$2.6M
The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced PathologyR01AI155466 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Ricardo Rajsbaum · 2021 to 2026
$2.5M
NIAID NIH HHS P01 AI150585NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI155466NIAID NIH HHS R01 AI166668NICHD NIH HHS K12 HD052023
6 · The paper itself

Abstract

SARS-CoV-2 is a highly transmissible virus that causes COVID-19 disease. Mechanisms of viral pathogenesis include excessive inflammation and viral-induced cell death, resulting in tissue damage. We identified the host E3-ubiquitin ligase TRIM7 as an inhibitor of apoptosis and SARS-CoV-2 replication via ubiquitination of the viral membrane (M) protein.

Indexed as

Antiviral activityApoptosisCaspase-6E3-Ubiquitin ligasesMembrane proteinSARS-CoV-2TRIM7Ubiquitination

Identifiers

PMID38948778
PMCPMC11212893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.